Evidence of the Momentum
The use of Nasal High Flow therapy is increasing across the globe. Three surveys of practice found that approximately 70% of respondents across the United Kingdom, United States of America, Australia and New Zealand reported using Nasal High Flow1,2,3.
With growing clinical evidence supporting the therapy, it is helping more premature babies and infants every day.
Optiflow Junior is now available in over 90 countries worldwide.